Jump to content

CEPP

From Wikipedia, the free encyclopedia

CEPP is a chemotherapy regimen that is intended for treatment of aggressive non-Hodgkin lymphomas.[1] It consists of cyclophosphamide, etoposide, procarbazine, and prednisone. Unlike CHOP, this chemotherapy regimen does not contain doxorubicin or any other anthracycline. Thus, it can be used in patients with severe cardiovascular diseases and contraindications for doxorubicin-containing regimens. This regimen also does not contain vincristine and can be used in patients with neuropathy.

There are several modifications of CEPP. In combination with bleomycin, this regimen is called CEPP (B).[2] With the further addition of the anti-CD20 monoclonal antibody rituximab, it is called R-CEPP(B).

R-CEPP(B) regimen consists of:

R-CEPP(B) dosing regimen

[edit]
Drug Dose Mode Days
Rituximab 375 mg/m2 IV infusion Day 1
Cyclophosphamid 600 mg/m2 IV infusion Days 1 and 8
Etoposide 70 mg/m2 IV infusion Days 1-3
Procarbazine 60 mg/m2 PO qd Days 1-10
Prednisone or prednisolone 60 mg/m2 PO qd Days 1-10
Bleomycin 10 IU/m2 IV bolus Day 1

References

[edit]
  1. ^ Thakar, Keyur; Novero, Aileen; Das, Arundhati; Lisinschi, Adriana; Mehta, Bella; Ahmed, Tauseef; Liu, Delong (2014). "CEPP regimen (Cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function". Biomarker Research. 2: 12. doi:10.1186/2050-7771-2-12. PMC 4078319. PMID 24991411.
  2. ^ Chao, NJ; Rosenberg, SA; Horning, SJ (1990). "CEPP(B): An effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma". Blood. 76 (7): 1293–1298. doi:10.1182/blood.V76.7.1293.1293. PMID 2207307.